The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XFOR | -73.86% | -98.04% | -54.43% | -99% |
| S&P | +16.9% | +95.99% | +14.39% | +142% |
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.97M | 250.4% |
| Gross Profit | $1.48M | 1364.4% |
| Gross Margin | 74.96% | 57.0% |
| Market Cap | $11.00M | -88.7% |
| Market Cap / Employee | $0.08M | 0.0% |
| Employees | 143 | 53.8% |
| Net Income | -$25.74M | -128.3% |
| EBITDA | -$25.86M | 23.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $39.22M | -73.4% |
| Accounts Receivable | $1.15M | 0.0% |
| Inventory | 3.2 | 281.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $76.66M | -0.5% |
| Short Term Debt | $1.37M | 16.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -64.59% | -73.8% |
| Return On Invested Capital | -71.91% | -0.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.90M | 1.7% |
| Operating Free Cash Flow | -$29.90M | 1.2% |
| Metric | Q2 2024 | Q1 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 6.78 | 3.16 | - | ||
| Price to Book | 1.89 | 5.66 | 1.79 | 0.48 | -99.49% |
| Price to Sales | 119.71 | 58.22 | 1.55 | 0.43 | -99.79% |
| Price to Tangible Book Value | 50.61 | 115.60 | -233.06 | -2.61 | -98.54% |
| Enterprise Value to EBITDA | -2.27 | -3.52 | -4.45 | -1.13 | 46.48% |
| Return on Equity | -26.3% | -102.3% | 121.8% | -207.2% | -1051.88% |
| Total Debt | $78.20M | $78.09M | $78.04M | $78.02M | -0.26% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
